asa glp-1 agonist guidelines and Anesthesia: Considerations and Cautions for CRNAs aGLP-1 receptor agonists & anesthesia:

doi: 10.1111/add.16679

Recent studies have indicated that GLP-1RAs may possess neuroprotective properties (12) and directly reduce ICP

[DOI] [PMC free article] [PubMed] [Google Scholar] 46.Buse J.B., Peters A., Russell-Jones D., Furber S., Donsmark M., Han J

Deeply understand physician and payer dynamics, and build strategy accordingly: Deeply understand physician and payer dynamics, and build strategy accordingly: Understanding the differences between primary care provider versus endocrinologist perceptions and prescribing behaviors (e.g., class preferences, route of administration preferences, etc.) is foundational to developing strategies that account for stakeholder-specific nuances

Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies

Study Groups Four groups were established according to which glucose-lowering agents were prescribed independently of other antidiabetic drugs concurrently prescribed: (a) all GLP-1RA users (GLP-1RA group), (b) SGLT2 inhibitor users with no GLP-1RA prescription (SGLT2i group), (c) insulin users with no GLP-1RA or SGLT2i prescriptions (insulin group) and (d) users of other glucose-lowering agents (miscellany group) (Fig